Muha Meds

Muha Meds concentrated 74.12% of June 2026 sales in Vapor Pens, where sales fell 20.02% year over year but ticked up 2.39% month over month, while Flower rose 45.89% year over year to 15.21% share but slid 11.39% month over month. Pre-Roll held 7.20% share with 23.57% year-over-year growth offset by a 35.37% month-over-month drop, and Concentrates grew 53.45% year over year at 1.20% share despite a 5.64% month-over-month decline; Edible dipped 3.20% year over year and 5.13% month over month at 2.28% share. With brand sales down 10.76% year over year but up 33.11% over 24 months and average price up 13.44%, the mix signals a reliance on a large but contracting core and a pivot into faster-growing adjacencies that are volatile month to month.

Holding rank 3 in Vapor Pens in Michigan while the category’s brand sales declined 20.02% year over year suggests Muha Meds still commands scale but is exposed to category headwinds, whereas double-digit year-over-year gains in Flower (45.89%), Pre-Roll (23.57%), and Concentrates (53.45%) indicate a deliberate diversification that is cushioning, not yet replacing, the core. The 2.39% month-over-month lift in Vapor Pens alongside sharp month-over-month declines in Flower (−11.39%) and Pre-Roll (−35.37%) implies recent demand reverted toward the core after promotional or distribution noise, so the brand’s positioning hinges on defending a top-3 Vapor Pen slot while pacing capacity and pricing to convert high-growth but small-share segments into stable, repeatable contribution.